Transmedics Group, Inc. current report, 29 July 2022

Full document

TransMedics Group, Inc. — Form 8-K Summary

Business Context and Reporting Period

TransMedics Group, Inc. filed this Form 8-K on July 29, 2022, reporting financing transactions completed on July 25, 2022. The filing concerns a new senior secured term loan and the refinancing and termination of the company’s prior OrbiMed credit arrangements.

Financing and Key Financial Terms

  • Entered into a credit agreement with Canadian Imperial Bank of Commerce (CIBC) for a $60.0 million senior secured term loan, borrowed in full at closing.
  • Proceeds were used to repay the OrbiMed facility, pay related transaction costs and expenses, and fund general corporate purposes.
  • The loan matures on July 25, 2027, five years after closing.
  • Interest is payable, at the company’s option, at either the applicable secured overnight financing rate, subject to a 1.5% floor, plus 2.0%, or the higher of the prime rate and the Federal Funds Effective Rate, plus 0.5%.
  • The obligations are guaranteed by material wholly owned subsidiaries and secured by substantially all assets of the company and guarantors.
  • The filing does not provide operating revenue, profit, cash flow, margin, or liquidity balances for a reporting period.

Material Changes Versus the Prior Comparable Period

  • On July 25, 2022, the company repaid all amounts outstanding under the OrbiMed Credit Agreement, including $35.0 million of principal.
  • The OrbiMed Credit Agreement and related pledge, security, and guarantee agreements were terminated, and the associated security interests were released.
  • The company replaced the prior financing with a larger $60.0 million CIBC term loan, increasing secured debt relative to the disclosed $35.0 million OrbiMed principal repayment.

Covenants, Outlook, and Risks

  • The CIBC facility includes customary representations, affirmative and negative covenants, and events of default.
  • A minimum liquidity covenant requires cash and cash equivalents to be at least the greater of trailing four-month EBITDA burn, if EBITDA is negative, or $10.0 million.
  • A minimum total net revenue covenant requires revenue to be at least 75% of the level in the total revenue plan presented to CIBC.
  • The loan is secured and guaranteed, creating collateral and potential default risks if the company fails to satisfy its obligations or covenants.
  • The filing does not provide management guidance for revenue, earnings, cash flow, or other operating metrics.

Investor Verification Items

  • Verify the complete interest-rate mechanics, amortization provisions, fees, prepayment terms, and events of default in Exhibit 10.1.
  • Review the definition and calculation of “Trailing Four Month EBITDA Burn” and the detailed liquidity and revenue covenant provisions.
  • Assess the impact of the new secured debt on interest expense, liquidity, collateral availability, and financial flexibility.
  • Confirm the company’s cash balance, current debt outstanding, and compliance with the CIBC covenants in subsequent periodic filings.
  • Review the Guarantee and Collateral Agreement in Exhibit 10.2 for the scope of pledged assets and subsidiary guarantees.